

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ORYXE.001AAPPLICATION NO.
09/350,043INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Frederick L. Jordan

RECEIVED

FILING DATE
July 8, 1999GROUP
37611 NOV 23 1999

TECHNOLOGY CENTER 3700

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
RB	1.	5,318,960	6-7-94	TOPPO	514	159	6-3-92
	2.	5,571,671	11-5-96	POTTER	435	6	3-23-94
	3.	5,614,212	3-25-97	D'ANGELO ET AL.	424	449	10-19-93
	4.	5,665,378	9-9-97	DAVIS ET AL.	424	448	11-21-95
	5.	5,708,038	1-13-98	DAVIS	514	783	6-13-96
	6.	5,744,368	4-28-98	GOLDGABER, ET AL.	436	501	11-4-93
	7.	5,837,853	11-17-98	TAKASHIMA, ET AL.	536	24.5	2-20-96
	8.	5,840,746	11-24-98	DUCHARME ET AL.	514	438	9-5-97
	9.	5,861,268	1-19-99	TANG ET AL.	435	25	5-23-96
	10.	5,885,597	3-23-99	BOTKNECHT ET AL.	424	401	10-1-97
RB	11.	5,891,651	4-6-99	ROCHE ET AL.	435	21	3-29-96
	12.	5,891,857	4-6-99	HOLT ET AL.	514	44	2-20-96

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
RB	13.	98/34629	8-13-98	WO			X	

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

S:\DOCS\IESF-1778.DOC
102099

EXAMINER

BAWA

DATE CONSIDERED

2/10/01

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ORYXE.001AAPPLICATION NO.
09/350,043INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Frederick L. JordanFILING DATE
July 8, 1999GROSS
3767RECEIVED
1677

NOV 23 1999

(USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

TECHNOLOGY CENTER 3700

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
7-13	14. Downing et al., <u>Dermatology in General Medicine</u> , Fitzpatrick, et al., eds., pp. 210-221 (1993)
	15. Ponc, M., <u>Epidermal lipids in vivo</u> , <u>The Keratinocyte Handbook</u> , Leigh, et al., eds., pp. 351-363 (1994)
	16. Woodin, L., <u>Cutting postop pain</u> , <u>RN</u> , August: 26-33 (1993)
	17. Amadio et al., <u>Nonsteroidal anti-inflammatory drugs</u> , <u>Postgraduate Medicine</u> , 93(4):73-97 (1993)
	18. http://www.natplus.com/products/productNumber=7124
	19. http://www.botanical.com/botanical/mgmh/f/franki31.html Page # ?
	20. Cohen, et al. in <u>Wound Healing/Biochemical and Clinical Aspects</u> , 1st ed. WB Saunders, Philadelphia (1992)
	21. Grindlay and Reynolds, <u>The Aloe Vera Phenomenon: A Review of the Properties and Modern Uses of the Leaf Parenchyma Gel</u> , (1986) <u>J. of Ethnopharmacology</u> 16:117-151
	22. Hart, et al., <u>Two Functionally and Chemically Distinct Immunomodulatory Compounds in the Gel of Aloe Vera</u> , (1988) <u>J. of Ethnopharmacology</u> 23:61-71
	23. Hirata, et al., <u>Biologically Active Constituents of Leaves and Roots of Aloe Arborescens var. natalensis</u> , (1977) <u>Z. Naturforsch.</u> 32c:731-734
	24. Bronaugh and Collier, <u>In vitro Percutaneous absorption studies: Principle, Fundamentals, and Applications</u> , eds. Bronaugh and Maibach, Boca Raton, Fl, CRC Press, pp237-241 (1991)
	25. Nelson et al., <u>Mid-Infrared Laser Ablation of Stratum Corneum Enhances in Vitro Percutaneous Transport of Drugs</u> , <u>The Society for Investigative Dermatology, Inc.</u> 874-879 (1991)
	26. Collier et al., <u>Maintenance of Skin Viability during in Vitro Percutaneous Absorption/Metabolism Studies</u> , <u>Toxicology and Applied Pharmacology</u> , 99:522-533 (1989)
7-13	27. Barel and Clarys, <u>Study of the Stratum corneum Barrier Function by Transepidermal Water Loss Measurements: Comparison between Two Commercial Instruments</u> , <u>Skin Pharmacol.</u> 8:186-195 (1995)

S:\DOCS\ESF\ESF-1780.DOC
102199

EXAMINER BAWA	DATE CONSIDERED 2/10/01
*EXAMINER INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	